Local gene delivery for cancer therapy

Current Gene Therapy

Volumn 11, Issue 5, 2011, Pages 423-432

  Zhao, Lili ^a   Wu, Jinhui ^a   Zhou, He ^a   Yuan, Ahu ^a   Zhang, Xiang ^a   Xu, Feng ^b,c   Hu, Yiqiao ^a  

^a NANJING UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer therapy; Drug eluting implants; Electrogene; Intratumoral; Local gene therapy; Magnetic; Tumor tropism delivery; Ultrasound

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; INTERLEUKIN 12; INTERLEUKIN 2; LIPOFECTAMINE; NANOBUBBLE; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERLEUKIN 12; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CARCINOMATOUS PERITONITIS; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; DRUG EFFICACY; ELECTROPORATION; FIBROBLAST; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; LUNG CANCER; MAGNETIC FIELD; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RETINOBLASTOMA; RNA INTERFERENCE; STEM CELL GENE THERAPY; TREATMENT RESPONSE; TROPISM; TUMOR XENOGRAFT;

EID: 80053506927     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311797415854     Document Type: Article

References (112)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010, CA. Cancer J Clin 2010; 60: 277-300.
2. Alderton GK. Radiotherapy: Worming your way to cell death, Nat Rev Cancer 2008; 8: 830-831.
3. Improved chemotherapies. Nat Rev Cancer 2010; 10: 740-740.
4. Harris TJR, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-65.
5. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008; 118: 1590-1605.
6. Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in cancer therapy. Expert Rev Mol Med 2010; 12: e26.
7. Mukherji SK. Bevacizumab (Avastin), AJNR. Am J Neuroradiol 2010; 31: 235-236.
8. Pellegrini M, Mak TW, Ohashi PS. Fighting cancers from within: augmenting tumor immunity with cytokine therapy. Trends Pharmacol Sci 2010; 31: 356-363.
9. Atkinson GP, Nozell SE, Benveniste ET. NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010; 10: 575-586.
10. Testa U. TRAIL/TRAIL-R in hematologic malignancies. J Cell Biochem 2010; 110: 21-34.
11. Griffith TS, Stokes B, Kucaba TA, et al. TRAIL gene therapy: from preclinical development to clinical application. Curr Gene Ther 2009; 9: 9-19.
12. Caraglia M, Marra M, Tagliaferri P, et al. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets 2009; 9: 690-704.
13. Gene therapy clinical trials worldwide database. Available at: http: //www.abedia.com/wiley/index.html. Accessed 2010.06.
14. Cao S, Cripps A, Wei MQ. New strategies for cancer gene therapy: Progress and opportunities. Clin Exp Pharmacol Physiol 2010; 37: 108-114.
15. Guinn BA, Mulherkar R. International progress in cancer gene therapy. Cancer Gene Ther 2008; 15: 765-775.
16. Venkatraman SS, Ma LL, Natarajan JV, Chattopadhyay S. Polymer- and liposome-based nanoparticles in targeted drug delivery. Front Biosci (Schol Ed) 2010; 2: 801-814.
17. Palmer DH, Young LS, Mautner V. Cancer gene-therapy: clinical trials. Trends Biotechnol 2006; 24: 76-82.
18. Gustafson JA, Ghandehari H. Silk-elastinlike protein polymers for matrix-mediated cancer gene therapy. Adv Drug Deliv Rev 2010;
19. Vidic S, Markelc B, Sersa G, et al. MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. Cancer Gene Ther 2010; 17: 409-419.
20. Shih C-S, Laurie N, Holzmacher J, et al. AAV-mediated Local Delivery of Interferon-β for the Treatment of Retinoblastoma in Preclinical Models. Neuromol Med 2009; 11: 43-52.
21. Watanabe M, Boyer J, Crystal R. AAVrh. 10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther 2010; 17(8): 1042-1051.
22. Sadadcharam M, Soden DM, O'sullivan GC. Electrochemotherapy: An emerging cancer treatment. Int J Hyperthermia 2008; 24: 263-273.
23. Exner AA, Saidel GM. Drug-eluting polymer implants in cancer therapy. Expert Opin Drug Deliv 2008; 5: 775-788.
24. Favard C, Dean D, Rols M. Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 2007; 7: 67-77.
25. Nicolay C, Purkayastha S, Darzi A. Minimally invasive surgery for colorectal cancer. Expert Rev. Anticancer Ther 2010; 10: 469-471.
26. Buchsbaum DJ, Miller CR, McNally LR, Kaliberov SA, Cancer gene therapy. In: R. K. Oldham and R. O. Dillman, Eds. Principles of Cancer Biotherapy. Springer Netherlands 2009; pp. 589-612.
27. Robinson CN, Balentine CJ, Marshall CL, et al. Minimally Invasive Surgery Improves Short-term Outcomes in Elderly Colorectal Cancer Patients. J Surg Res 2010;
28. Vardouli L, Lindqvist C, Vlahou K, et al. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther 2009; 16: 848-860.
29. Kim YI, Chung JW. Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. Expert Rev Gastroenterol Hepatol 2008; 2: 791-802.
30. Vernejoul F, Ghenassia L, Souque A, et al. Gene Therapy Based on Gemcitabine Chemosensitization Suppresses Pancreatic Tumor Growth. Mol Ther 2006; 14: 758-767.
31. Heguy A, Crystal RG. Intrapleural 'outside-in' gene therapy: therapeutics for organs of the chest via gene transfer to the pleura. Curr Opin Mol Ther 2005; 7: 440-453.
32. Yoshida J, Mizuno M, Wakabayashi T. Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci 2004; 95: 858-865.
33. Meijer DH, Maguire CA, LeRoy SG, Sena-Esteves M. Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther 2009; 16: 664-671.
34. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010; 12: 26-33.
35. Levine BL. T lymphocyte engineering ex vivo for cancer and infectious disease. Expert Opin Biol Ther 2008; 8: 475-489.
36. Van Tendeloo VF, Van Broeckhoven C, Berneman ZN. Genebased cancer vaccines: an ex vivo approach. Leukemia 2001; 15: 545-558.
37. Nguyen TH, Mainot S, Lainas P, et al. Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. Curr Gene Ther 2009; 9: 136-149.
38. Peron J-M, Couderc B, Rochaix P, et al. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J. Gastroenterol. Hepatol 2004; 19: 388-396.
39. Péron JM, Bureau C, Gourdy P, et al. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity. Gut 2007; 56: 107-114.
40. Lortal B, Gross F, Peron JM, et al. Preclinical study of an ex vivo gene therapy protocol for hepatocarcinoma. Cancer Gene Ther 2008; 16: 329-337.
41. Weinberg BD, Blanco E, Gao J. Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 2008; 97: 1681-1702.
42. Yu P, Wang X, Fu YX. Enhanced local delivery with reduced systemic toxicity: delivery, delivery, and delivery. Gene Ther 2006; 13: 1131-1132.
43. Kim YI, Chung JW. Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. Expert Rev Gastroenterol Hepatol 2008; 2: 791-802.
44. Kiriyama S, Oda I, Nishimoto F, et al. Pilot study to assess the safety of local lidocaine injections during endoscopic submucosal dissection for early gastric cancer. Gastric Cancer 2009; 12: 142-147.
45. Henshaw JW, Zaharoff DA, Mossop BJ, Yuan F. Electric fieldmediated transport of plasmid DNA in tumor interstitium in vivo. Bioelectrochemistry 2007; 71: 233-242.
46. Roos A-K, Eriksson F, Timmons JA, et al. Skin Electroporation: Effects on Transgene Expression, DNA Persistence and Local Tissue Environment. PLoS ONE 2009; 4: e7226.
47. Reed SD, Li SL. Electroporation Advances in Large Animals. Curr Gene Ther 2009; 9: 316-326.
48. Chuang TF, Lee SC, Liao KW, et al. Electroporation-mediated IL- 12 gene therapy in a transplantable canine cancer model. Int J Cancer 2009; 125: 698-707.
49. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010; 10: 300-311.
50. Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10: 312-317.
51. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
52. Tsai V, Johnson DE, Rahman A, et al. Impact of Human Neutralizing Antibodies on Antitumor Efficacy of an Oncolytic Adenovirus in a Murine Model. Clin Cancer Res 2004; 10: 7199- 7206.
53. Chen Y, Yu D, Charlton D, Henderson D. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000; 11: 1553-1567.
54. Kangasniemi L, Koskinen M, Jokinen M, et al. Extended release of adenovirus from silica implants in vitro and in vivo. Gene Ther 2009; 16: 103-110.
55. Hatefi A, Cappello J, Ghandehari H. Adenoviral Gene Delivery to Solid Tumors by Recombinant Silk-Elastinlike Protein Polymers. Pharm Res 2007; 24: 773-779.
56. Wang Y, Wang H, Li CY, Yuan F. Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery. Mol Cancer Ther 2006; 5: 362-366.
57. Wang S, Zderic V, Frenkel V. Extracorporeal, low-energy focused ultrasound for noninvasive and nondestructive targeted hyperthermia. Future Oncol 2010; 6: 1497-1511.
58. Suzuki R, Takizawa T, Negishi Y, et al. Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles. J Controlled Release 2008; 125: 137-144.
59. Li YS, Davidson E, Reid CN, McHale AP. Optimising ultrasoundmediated gene transfer (sonoporation) in vitro and prolonged expression of a transgene in vivo: Potential applications for gene therapy of cancer. Cancer Lett 2009; 273: 62-69.
60. Cavalieri F, Zhou M, Ashokkumar M. The Design of Multifunctional Microbubbles for Ultrasound Image-Guided Cancer Therapy. Curr Top Med Chem 2010; 10: 1198-1210.
61. Rahim AA, Taylor SL, Bush NL, et al. Spatial and acoustic pressure dependence of microbubble-mediated gene delivery targeted using focused ultrasound. J Gene Med 2006; 8: 1347-1357.
62. Suzuki R, Namai E, Oda Y, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Controlled Release 2010; 142: 245-250.
63. Tsai KC, Liao ZK, Yang SJ, et al. Differences in gene expression between sonoporation in tumor and in muscle. J Gene Med 2009; 11: 933-940.
64. Suzuki R, Takizawa T, Negishi Y, et al. Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int J Pharm 2008; 354: 49-55.
65. Horie S, Watanabe Y, Chen R, et al. Development of Localized Gene Delivery Using a Dual-Intensity Ultrasound System in the Bladder. Ultrasound Med Biol 2010; 36: 1867-1875.
66. Shortencarier MJ, Dayton PA, Bloch SH, et al. A method for radiation-force localized drug delivery using gas-filled lipospheres. IEEE transactions on ultrasonics, ferroelectrics, and frequency control 2004; 51: 822-831.
67. Ensenauer R, Hartl D, Vockley J, et al. Efficient and gentle siRNA delivery by magnetofection. Biotech HistoChem 0: 1-6.
68. Namiki Y, Namiki T, Yoshida H, et al. A novel magnetic crystallipid nanostructure for magnetically guided in vivo gene delivery. Nat Nano 2009; 4: 598-606.
69. Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin Drug Deliv 2009; 6: 53-70.
70. Pickard M, Chari D. Enhancement of magnetic nanoparticlemediated gene transfer to astrocytes by 'magnetofection': effects of static and oscillating fields. Nanomed 2010; 5: 217-232.
71. Lee JH, Lee K, Moon S, et al. All-in-One Target-Cell-Specific Magnetic Nanoparticles for Simultaneous Molecular Imaging and siRNA Delivery. Angew Chem Int Ed 2009; 48: 4174-4179.
72. Chertok B, David AE, Moffat BA, Yang VC. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials 2009; 30: 6780-6787.
73. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials 2010; 31: 6317-6324.
74. Shuang Y, May S. Release of cationic polymer-DNA complexes from the endosome: A theoretical investigation of the proton sponge hypothesis. J Chem Phys 2008; 129: 185105.
75. McBain S, Yiu H, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine 2008; 3: 169.
76. Zhang L, Gao L, Zhao L, et al. Intratumoral Delivery and Suppression of Prostate Tumor Growth by Attenuated Salmonella enterica serovar typhimurium Carrying Plasmid-Based Small Interfering RNAs. Cancer Res 2007; 67: 5859-5864.
77. Pawelek JM, Low KB, Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol 2003; 4: 548-556.
78. Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Bone Marrow-Derived Progenitors 2007: 263-283.
79. Toso JF, Gill VJ, Hwu P, et al. Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma. J Clin Oncol 2002; 20: 142-152.
80. Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer. Cancer Res 2009; 69: 4134-4142.
81. Patyar S, Joshi R, Byrav D, et al. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010; 17: 21.
82. Morrissey D, O'Sullivan GC, Tangney M. Tumour targeting with systemically administered bacteria. Curr Gene Ther 2010; 10: 3-14.
83. Zhou S, Bettegowda C, Agrawal N. Combination bacteriolytic cancer therapy: Attacking cancer from inside out. Discov Med 2004; 4: 33-37.
84. Mengesha A, Dubois L, Lambin P, et al. Development of a flexible and potent hypoxia-inducible promoter for tumor-targeted gene expression in attenuated Salmonella. Cancer Biol Ther 2006; 5: 1120-1128.
85. Jia LJ, Hua ZC. Development of bacterial vectors for tumortargeted gene therapy. Methods Mol Biol 2009; 542: 131-154.
86. Kruehn A, Wang A, Fruehauf J, Lage H. Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells, Cell cycle (Georgetown, Tex.) 2009; 8: 3349.
87. Friedlos F, Lehouritis P, Ogilvie L, et al. Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy. Clin Cancer Res 2008; 14: 4259-4266.
88. Ganai S, Arenas RB, Forbes NS. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer 2009; 101: 1683-91.
89. Stritzker J, Pilgrim S, Szalay A, Goebel W. Prodrug converting enzyme gene delivery by L. monocytogenes. BMC Cancer 2008; 8: 94.
90. Dang LH, Bettegowda C, Huso DL, et al. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001; 98: 15155-15160.
91. Xu D, Zhang L, Kopecko D, et al. Bacterial delivery of siRNAs: a new approach to solid tumor therapy. Methods Mol Biol 2009; 487: 161-187.
92. Jia L-J, Wei D-P, Sun Q-M, et al. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci 2007; 98: 1107-1112.
93. Hu Y-L, Fu Y-H, Tabata Y, Gao J-Q. Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy. J Controlled Release 2010; 147: 154-162.
94. Kranzler J, Tyler MA, Sonabend AM, et al. Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy. Curr Gene Ther 2009; 9: 389-395.
95. Dwyer RM, Khan S, Barry FP, et al. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther 2010; 1: 25.
96. Mercapide J, Rappa G, Anzanello F, et al. Primary geneengineered neural stem/progenitor cells demonstrate tumorselective migration and antitumor effects in glioma. Int J Cancer 2010; 126: 1206-1215.
97. Bexell D, Scheding S, Bengzon J. Toward Brain Tumor Gene Therapy Using Multipotent Mesenchymal Stromal Cell Vectors. Mol Ther 2010; 18: 1067-1075.
98. Chang DY, Yoo SW, Hong Y, et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010; 127: 1975-1983.
99. Kim SM, Lim JY, Park SI, et al. Gene Therapy Using TRAILSecreting Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells against Intracranial Glioma. Cancer Res 2008; 68: 9614-923.
100. Matuskova M, Hlubinova K, Pastorakova A, et al. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett 2010; 290: 58-67.
101. Nakamizo A, Marini F, Amano T, et al. Human bone marrowderived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
102. Gao P, Ding Q, Wu Z, et al. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 2010; 290: 157-166.
103. Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow- derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 2009; 115: 13-22.
104. Studeny M, Marini FC, Champlin RE, et al. Bone Marrow-derived Mesenchymal Stem Cells as Vehicles for Interferon-β Delivery into Tumors. Cancer Res 2002; 62: 3603-3608.
105. Ren C, Kumar S, Chanda D, et al. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem cells (Dayton, Ohio) 2008; 26: 2332-2338.
106. Stagg J, Lejeune L, Paquin A, Galipeau J. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 2004; 15: 597-608.
107. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563.
108. Fernández-Pacheco R, Marquina C, Gabriel Valdivia J, et al. Magnetic nanoparticles for local drug delivery using magnetic implants. J Magn Magn Mater 2007; 311: 318-322.
109. Garbuzenko OB, Saad M, Pozharov VP, et al. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 2010; 107: 10737-10742.
110. Eefting D, Grimbergen J, de Vries M, et al. Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. Hum Gene Ther 2007; 18: 861-869.
111. Ensenauer R, Hartl D, Vockley J, et al. Efficient and gentle siRNA delivery by magnetofection. Biotech Histochem 2010
112. Siemens, Pictures of the Future. Available at: www.siemens.com/pof. Accessed 2010.